MEK Inhibition by Selumetinib Enhances the Antitumor and Anti-Metastatic Effects of Chemoradiation Therapy in Orthotopic Human Lung Cancer Models

S Furutani,R Komaki,P.D Smith,J.M Jürgensmeier,O Takahashi,T Rabin,R.S Herbst,M.S O'Reilly

doi:10.1016/j.ijrobp.2014.05.2300

MEK Inhibition by Selumetinib Enhances the Antitumor and Anti-Metastatic Effects of Chemoradiation Therapy in Orthotopic Human Lung Cancer Models

S Furutani, R Komaki + Show 6 more

Open Access

https://doi.org/10.1016/j.ijrobp.2014.05.2300

Copy DOI

Journal: International Journal of Radiation Oncology, Biology, Physics

Publication Date: Sep 1, 2014

Affiliation: The University of Texas MD Anderson Cancer Center, AstraZeneca (United Kingdom), Yale Cancer Center, Yale University

#Orthotopic Human Lung Cancer #Orthotopic Lung Cancer Models + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Selumetinib (AZD6244, ARRY-142886) is a potent orally available MEK1/2 inhibitor currently in clinical development. We evaluated the therapeutic efficacy and radiosensitizing effects of selumetinib and paclitaxel in two distinct KRAS mutant murine orthotopic human non-small cell lung cancer models.

Full Text